Outcomes following de novo CNI-free immunosuppression after heart transplantation: A single-center experience

American Journal of Transplantation

Volumn 9, Issue 1, 2009, Pages 140-148

  Leet, A S ^a   Bergin, P J ^a   Richardson, M ^a   Taylor, A J ^a   Esmore, D ^a   Kaye, D M ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Clinical heart transplantation; Clinical immunosuppression; CNI nephrotoxicity; Cytomegalovirus infection; Early immunosuppression; Early outcome analysis; Effusions; Everolimus; Immunosuppressive therapy; Infectious complications; Outcomes

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; BACTERIAL INFECTIONS; CREATININE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 58049202927     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02456.x     Document Type: Article

References (27)

1. Odim J, Wheat J, Laks H et al. Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant 2006 25 : 162 166.
2. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006 6 : 671 679.
3. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. New Engl J Med 2003 349 : 931 940.
4. Goldstein DJ, Zuech N, Sehgal V, Weinberg A, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplant Proc 1997 63 : 664 668.
5. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999 10 : 1136 1144.
6. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and lefunomide. Curr Opin Immunol 1996 8 : 710.
7. Franco AFV, Martini D, Abensur H, Noronha IL. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007 39 : 449 452.
8. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004 17 : 215 220.
9. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. New Engl J Med 2003 349 : 847 858.
10. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in De Novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004 110 : 2694 2700.
11. Stewart S, Winters G, Fishbein M, Billingham M. ISHLT consensus report. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005 24 : 1710 1720.
12. Meiser B, Reichart B, Adamidis I, Uberfuhr P, Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005 5 : 827 831.
13. Aranda-Dios A, Lage E, Sobrino JM et al. Sirolimus experience in heart transplantation. Transplant Proc 2006 38 : 2547 2549.
14. Fernandez-Valls M, Gonzalez-Vilchez F, Vazquez-de-Prada JA, Ruano J, Ruisanchez C, Martin-Duran R. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: Experience of a single center. Transplant Proc 2005 37 : 4021 4023.
15. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006 6 : 1377 1386.
16. Mancini D, Pinnery S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003 108 : 48 53.
17. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris R. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995 59 : 390 394.
18. Zucker MJ, Baran DA, Arroyo LH et al. De Novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: A one-year follow-up analysis. Transplant Proc 2005 37 : 2231 2239.
19. Knight RJ, Villa M, Laskey R et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007 10 : 1 6.
20. Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003 3 : 1128 1134.
21. Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVical JO, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study. Transplantation 2003 76 : 426 429.
22. Dean PG, Lund W, Larson T et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004 77 : 1555 1561.
23. Kuppahally S, Al-Khaldi A, Weisshaar D et al. Wound healing complications with De Novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006 6 : 986 992.
24. Ponticelli C. The pleiotropic effects of motor inhibitors. J Nephrol 2004 17 : 762 768.
25. Lowance D, Numayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New Engl J Med 1999 340 : 1462 1470.
26. Brennan DC. Cytomegolavirus in renal transplantation. J Am Soc Nephrol 2001 12 : 848 855.
27. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications. Transplantation 2004 78 : 264 268.